Lupin settles with Depomed/Santarus for generic Glumetza
This article was originally published in Scrip
Executive Summary
Lupin's US arm has entered into a settlement with Santarus Inc and Depomed to resolve pending patent litigation concerning the type 2 diabetes treatment, Glumetza (extended release metformin tablets) 1000mg and 500mg. Lupin believes it is the first to file an ANDA for both strengths, entitling it to 180 days of marketing exclusivity.